Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods:: results from a population-based study of young breast cancer patients

被引:18
|
作者
Lee, Eunjung [1 ]
McKean-Cowdin, Roberta [1 ]
Ma, Huiyan [2 ]
Chen, Zhengjia [1 ,3 ]
Van Den Berg, David [1 ]
Henderson, Brian E. [1 ]
Bernstein, Leslie [4 ,5 ]
Ursin, Giske [1 ,6 ]
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA
[2] Univ So Calif, Keck Sch Med, Inst Hlth Promot & Dis Prevent Res, Alhambra, CA 91803 USA
[3] Childrens Oncol Grp, Arcadia, CA 91066 USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA
[6] Univ Oslo, Dept Nutr, N-0316 Oslo, Norway
来源
BREAST CANCER RESEARCH | 2008年 / 10卷 / 01期
关键词
D O I
10.1186/bcr1865
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Efforts are ongoing to determine the significance of unclassified variants ( UVs) in the breast cancer susceptibility genes BRCA1/ BRCA2, but no study has systematically assessed whether women carrying the suspected deleterious UVs have characteristics commonly seen among women carrying known deleterious or disease- causing mutations in BRCA1/ BRCA2. Methods We sequenced BRCA1/ BRCA2 in 1,469 population-based female breast cancer patients diagnosed between the ages of 20 and 49 years. We used existing literature to classify variants into known deleterious mutations, polymorphic variants, and UVs. The UVs were further classified as high risk or low risk based on five methods: allele frequency, Polyphen algorithm, sequence conservation, Grantham matrix scores, and a combination of the Grantham matrix score and sequence conservation. Furthermore, we examined whether patients who carry the variants classified as high risk using these methods have risk characteristics similar to patients with known deleterious BRCA1/ BRCA2 mutations ( early age at diagnosis, family history of breast cancer or ovarian cancer, and negative estrogen receptor/ progesterone receptor). Results We identified 262 distinct BRCA1/ BRCA2 variants, including 147 UVs, in our study population. The BRCA1 UV carriers, but not the BRCA2 UV carriers, who were classified as high risk using each classification method were more similar to the deleterious mutation carriers with respect to family history than those carriers classified as low risk. For example, the odds ratio of having a first- degree family history for the high- risk women classified using Polyphen was 3.39 ( 95% confidence interval = 1.16 to 9.94) compared with normal/ polymorphic BRCA1 carriers. The corresponding odds ratio of low- risk women was 1.53 ( 95% confidence interval = 1.07 to 2.18). The odds ratio for high- risk women defined by allele frequency was 2.00 ( 95% confidence interval = 1.14 to 3.51), and that of low-risk women was 1.30 ( 95% confidence interval = 0.87 to 1.93). Conclusion The results suggest that the five classification methods yielded similar results. Polyphen was particularly better at isolating BRCA1 UV carriers likely to have a family history of breast cancer or ovarian cancer, and may therefore help to classify BRCA1 UVs. Our study suggests that these methods may not be as successful in classifying BRCA2 UVs.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Mutation analysis of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer
    Steinmann, D
    Bremer, M
    Rades, D
    Stuhrmann, M
    Schmidtke, J
    Karstens, JH
    Dörk, T
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (04): : B11 - B11
  • [42] Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients
    Vidal-Millan, S.
    Taja-Chayeb, L.
    Gutierrez-Hernandez, O.
    Ramirez Ugalde, M. T.
    Robles-Vidal, C.
    Bargallo-Rocha, E.
    Mohar-Betancourt, A.
    Duenas-Gonzalez, A.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 30 (05) : 527 - 530
  • [43] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [44] BRCA1 and BRCA2 in hereditary breast cancer
    Scully, R
    Puget, N
    BIOCHIMIE, 2002, 84 (01) : 95 - 102
  • [45] Evaluation of BRCA1/BRCA2 test results for Turkish breast cancer families
    Ates, E. Arslan
    Turkyilmaz, A.
    Geckinli, B. B.
    Ozgumus, G. Girgin
    Soylemez, M. A.
    Delil, K.
    Ata, P.
    Arman, A.
    Guney, A. I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 966 - 966
  • [46] BRCA2 AND BRCA1 breast cancer phenotypes
    Marcus, JN
    Watson, P
    Page, DL
    Narod, SA
    Tonin, P
    Serova, O
    Lenoir, GM
    Lynch, HT
    LABORATORY INVESTIGATION, 1997, 76 (01) : 110 - 110
  • [47] The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients
    Saleem, Mohamed
    Ghazali, Mohd Bazli
    Wahab, Md Azlan Mohamed Abdul
    Yusoff, Narazah Mohd
    Mahsin, Hakimah
    Seng, Ch'ng Ewe
    Khalid, Imran Abdul
    Rahman, Mohd Nor Gohar
    Yahaya, Badrul Hisham
    CANCER BIOLOGY AND ADVANCES IN TREATMENT, 2020, 1292 : 1 - 12
  • [48] Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients
    Choi, DH
    Lee, NH
    Bale, AE
    Carter, D
    Haffty, BG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1638 - 1645
  • [49] Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study
    E. M. Walsh
    M. P. Farrell
    C. Nolan
    F. Gallagher
    R. Clarke
    J. A. McCaffrey
    M. J. Kennedy
    M. Barry
    M. R. Kell
    D. J. Gallagher
    Irish Journal of Medical Science (1971 -), 2016, 185 : 189 - 194
  • [50] Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study
    Walsh, E. M.
    Farrell, M. P.
    Nolan, C.
    Gallagher, F.
    Clarke, R.
    McCaffrey, J. A.
    Kennedy, M. J.
    Barry, M.
    Kell, M. R.
    Gallagher, D. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 (01) : 189 - 194